Roivant Sciences Ltd.

Pharmaceutical Preparations

ROIV Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001635088 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$29.49B
722,323,015 shares Covers every share class this company has on file.
Insiders on file
11
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$3.47B
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
11.76%
insider-held value divided by market capitalisation

What Roivant Sciences Ltd. reports

Revenue and net income below are for fiscal period FY2026, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$8.26M
FY2026 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$299.77M
FY2026 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
721
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Roivant Sciences Ltd.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Roivant Sciences Ltd..
Insider Reported role Shares Value Last action
Officers 2
Richard Pulik Richard Pulik CFO 236,867 $8.27M F Shares withheld for taxes Aug 20, 2026 position reported
Jennifer Humes Chief Accounting Officer 97,729 $3.41M F Shares withheld for taxes Jun 20, 2026 position reported
Officers who also sit on the board 5
Mayukh Sukhatme Mayukh Sukhatme CIO 18,836,547 $657.96M S Open-market sale Aug 21, 2026 position reported
Matthew Gline CEO 17,287,081 $603.84M F Shares withheld for taxes Jun 30, 2026 position reported
Frank Torti Frank Torti President 13,736,547 $479.82M F Shares withheld for taxes Jun 30, 2026 position reported
Eric Venker Eric Venker CEO 1,647,546 $57.55M S Open-market sale Aug 28, 2026 position reported
Rakhi Kumar Chief Accounting Officer 162,306 $5.67M — position reported
Directors 3
Ilan Oren Ilan Oren Board Member 119,428 $4.17M A Grant or award Jul 17, 2026 position reported
James C. Momtazee James C. Momtazee Board Member 109,030 $3.81M A Grant or award Jul 17, 2026 position reported
Meghan Fitzgerald Meghan Fitzgerald Board Member 42,963 $1.50M S Open-market sale Sep 8, 2026 position reported
Holders of 10% or more 1
Vivek Ramaswamy Vivek Ramaswamy Major Shareholder (10%+) 47,011,612 $1.64B S Open-market sale Dec 15, 2025 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Richard Pulik sold 406,731 Roivant Sciences Ltd. (ROIV) shares for $9,122,307 on Dec 23, 2025

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Richard Pulik sold 406,731 Roivant Sciences Ltd. (ROIV) shares for $9,122,307 on Dec 23, 2025
Date Insider Transaction Shares Price Value Filing
Dec 23, 2025 Richard Pulik S Open-market sale 146,731 held after: 239,413 $22.39 $3,285,307 SEC filing ↗
Dec 23, 2025 Richard Pulik S Open-market sale 260,000 held after: 386,144 $22.45 $5,837,000 SEC filing ↗

Total of the rows above: $9,122,307, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Eric Venker sold 611,000 Roivant Sciences Ltd. (ROIV) shares for $9,061,130 on Sep 23, 2025

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Eric Venker sold 611,000 Roivant Sciences Ltd. (ROIV) shares for $9,061,130 on Sep 23, 2025
Date Insider Transaction Shares Price Value Filing
Sep 23, 2025 Eric Venker S Open-market sale 611,000 held after: 1,504,959 $14.83 $9,061,130 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Eric Venker sold 217,384 Roivant Sciences Ltd. (ROIV) shares for $2,289,054 on Feb 12, 2025

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Eric Venker sold 217,384 Roivant Sciences Ltd. (ROIV) shares for $2,289,054 on Feb 12, 2025
Date Insider Transaction Shares Price Value Filing
Feb 12, 2025 Eric Venker S Open-market sale 217,384 held after: 732,294 $10.53 $2,289,054 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 347 rows we hold, 1 are open-market purchases (P) and 92 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Roivant Sciences Ltd., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 8, 2026 Meghan Fitzgerald S Open-market sale 20,000 $39.90 $798.0K SEC filing ↗
Sep 8, 2026 Meghan Fitzgerald M Option exercise or conversion 20,000 $8.80 $176.0K SEC filing ↗
Aug 28, 2026 Eric Venker S Open-market sale 33,818 $36.44 $1.23M SEC filing ↗
Aug 28, 2026 Eric Venker S Open-market sale 166,182 $35.63 $5.92M SEC filing ↗
Aug 28, 2026 Eric Venker M Option exercise or conversion 200,000 $3.85 $770.0K SEC filing ↗
Aug 21, 2026 Mayukh Sukhatme S Open-market sale 144,756 $36.48 $5.28M SEC filing ↗
Aug 21, 2026 Mayukh Sukhatme M Option exercise or conversion 144,756 $3.85 $557.3K SEC filing ↗
Aug 20, 2026 Richard Pulik F Shares withheld for taxes 5,749 $36.84 $211.8K SEC filing ↗
Aug 20, 2026 Eric Venker F Shares withheld for taxes 13,909 $36.84 $512.4K SEC filing ↗
Aug 20, 2026 Mayukh Sukhatme S Open-market sale 17,519 $37.30 $653.5K SEC filing ↗
Aug 20, 2026 Mayukh Sukhatme M Option exercise or conversion 17,519 $3.85 $67.4K SEC filing ↗
Aug 19, 2026 Mayukh Sukhatme S Open-market sale 172,899 $37.17 $6.43M SEC filing ↗
Aug 19, 2026 Mayukh Sukhatme M Option exercise or conversion 172,899 $3.85 $665.7K SEC filing ↗
Aug 18, 2026 Mayukh Sukhatme S Open-market sale 31,801 $37.18 $1.18M SEC filing ↗
Aug 18, 2026 Mayukh Sukhatme M Option exercise or conversion 31,801 $3.85 $122.4K SEC filing ↗
Aug 18, 2026 Mayukh Sukhatme S Open-market sale 105,141 $36.59 $3.85M SEC filing ↗
Aug 18, 2026 Mayukh Sukhatme M Option exercise or conversion 105,141 $3.85 $404.8K SEC filing ↗
Aug 17, 2026 Mayukh Sukhatme S Open-market sale 284,707 $36.25 $10.32M SEC filing ↗
Aug 17, 2026 Mayukh Sukhatme M Option exercise or conversion 284,707 $3.85 $1.10M SEC filing ↗
Aug 14, 2026 Mayukh Sukhatme S Open-market sale 243,177 $36.23 $8.81M SEC filing ↗
Aug 14, 2026 Mayukh Sukhatme M Option exercise or conversion 243,177 $3.85 $936.2K SEC filing ↗
Jul 27, 2026 Eric Venker S Open-market sale 200,000 $34.95 $6.99M SEC filing ↗
Jul 27, 2026 Eric Venker M Option exercise or conversion 200,000 $3.85 $770.0K SEC filing ↗
Jul 17, 2026 James C. Momtazee A Grant or award 405 $0.00 $0 SEC filing ↗
Jul 17, 2026 Ilan Oren A Grant or award 775 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 1 filer holds a position, what this company owns

Who owns Roivant Sciences Ltd.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Filers holding a position in Roivant Sciences Ltd.

Funds, trusts and companies that disclose an ownership position in Roivant Sciences Ltd..
Owner Reported role Shares Filed
QVT Financial LP Other 15,127,329

What Roivant Sciences Ltd. owns

This company files as an owner of the companies below.

A name in plain text is the end of the trail: we hold the filing that names it, but no separate record to open.

Roivant Sciences Ltd.
Being named on an ownership form is not the same as legal parent–subsidiary control.

That relationship only holds if the filing says so. The map draws at most eight holdings per level, stops after two levels, and never doubles back on a name it has already passed through.

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 19 legal entities

Subsidiaries of Roivant Sciences Ltd.

19 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Roivant Sciences Ltd. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Covant Therapeutics Operating, Inc. United States – Delaware
Genevant Sciences Corporation Canada
Genevant Sciences GmbH Switzerland
Genevant Sciences Ltd. Bermuda
Genevant Sciences, Inc. United States – Delaware
Immunovant Sciences GmbH Switzerland
Immunovant Sciences Ltd. Bermuda
Immunovant, Inc. United States – Delaware
IMVT Corporation United States – Delaware
Priovant Holdings, Inc. United States – Delaware
Priovant Therapeutics, Inc. United States – Delaware
Pulmovant Sciences, Inc. United States – Delaware
Pulmovant, Inc. United States – Delaware
Roivant Sciences GmbH Switzerland
Roivant Sciences, Inc. United States – Delaware
Roivant Treasury Holdings, Inc. United States – Delaware
Roivant Treasury, Inc. United States – Delaware
Zest Dermatology Holdings, Inc. United States – Delaware
Zest Dermatology, Inc. United States – Delaware
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Roivant Sciences Ltd.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Roivant Sciences Ltd.’s own SEC filings multiplied by the closing price we hold for the same stock.

Logo: Stjl / CC BY-SA 4.0 , via Wikimedia Commons ↗ — used here to identify the company. Trademarks remain the property of their owner.